GO
Loading...

Government Agencies

More

  • Top business stories of 2014: US grows, world slows Monday, 22 Dec 2014 | 1:49 PM ET

    Those are some of the top business stories of 2014, as chosen by business editors at The Associated Press. Others include massive product disasters: A string of auto recalls after faulty ignition switches from General Motors Corp. and air bags in many car models caused injuries and deaths. Janet Yellen became the first woman to head the Federal Reserve and U.S....

  • WASHINGTON, Dec 22- The U.S. Commodity Futures Trading Commission on Monday ordered Deutsche Bank to pay a $3 million fine over charges that it had failed to properly invest customer funds and had made other mistakes in the process. Deutsche Bank neither denied nor admitted the regulator's findings, a court order said. In July, the Federal Reserve Bank of New York...

  • WASHINGTON, Dec 22- The U.S. Commodity Futures Trading Commission on Monday ordered a unit of Deutsche Bank to pay a $3 million fine over charges that it had failed to properly invest customer funds and had made other mistakes in the process. "DBSI failed to accurately compute the amount of customer funds on deposit," over the period of June 18, 2012 to August 15, 2012,...

  • The Justice Department said Alstom paid more than $75 million to secure $4 billion in projects around the world. DOJ said Alstom pleaded guilty to a two-count criminal information filed in a federal court in Connecticut and that Alstom's Swiss unit also pleaded guilty to criminal charges that it conspired to violate federal bribery laws.

  • BioCryst gets FDA approval for flu drug Rapivab Monday, 22 Dec 2014 | 11:07 AM ET

    NEW YORK— BioCryst Pharmaceuticals said Monday that U.S. regulators approved its drug Rapivab, an intravenous treatment for the flu. Shares of BioCryst Pharmaceuticals Inc. rose 17 cents to $11.33 in morning trading. Rapivab, or peramivir, was approved in Japan and South Korea in 2010 and is marketed in Japan by Shionogi and Co. It is only available in Korea on a...

  • Dec 22- The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's intravenous flu drug, sending the company's shares up nearly 10 percent in premarket trading. The single-dose drug is for adults who have acute uncomplicated influenza and may be unable to swallow pills, such as Gilead Sciences Inc's Tamiflu, or inhale GlaxoSmithKline...

  • FDA approves BioCryst's flu shot Monday, 22 Dec 2014 | 5:04 AM ET

    Dec 22- The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's single-dose flu shot on Monday, for use in adults with acute uncomplicated influenza. The drug was developed under a $234.8 million contract from Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services.

  • Dec 19- U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12- week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences. AbbVie's newly approved regimen is also less costly than Gilead's newest one-pill regimen that combines Sovaldi with...

  • FDA OKs Cubist antibiotic for serious infections Friday, 19 Dec 2014 | 6:34 PM ET

    TRENTON, N.J.— The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May. The approval of Zerbaxa on Friday is the second antibiotic approval this year for Cubist Pharmaceuticals, a drugmaker focused on antibiotics. It is being acquired for...

  • Kocherlakota warns Fed of 'unacceptable' risk Friday, 19 Dec 2014 | 6:23 PM ET

    WASHINGTON— One of three Fed officials who dissented in the Fed's policy decision this week is warning that the central bank is taking an "unacceptable" risk by not paying more attention to the dangers posed by low inflation. Narayana Kocherlakota, the president of the Fed's regional bank in Minneapolis, said Friday that the Fed's failure to respond to weak...

  • NEW YORK, Dec 19- The U.S. dollar hit its highest level against major currencies in over 8-1/ 2 years on Friday on diverging monetary policy between the Federal Reserve and other major central banks, and bullish dollar positions heading into the end of the year. The euro hit a 28- month low against the greenback, while the dollar hovered near a 28- month high against...

  • FDA approves AbbVie combo hepatitis C treatment Friday, 19 Dec 2014 | 3:35 PM ET

    TRENTON, N.J.— Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie. The Food and Drug Administration on Friday approved the sale of a packaged treatment called Viekira Pak made by AbbVie Inc. of North Chicago, Illinois. It includes a combination pill, which...

  • Dec 19- U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus. The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening.

  • Dec 19- The U.S. Environmental Protection Agency issued rules on Friday labeling coal ash, a byproduct of coal-based power production containing toxic materials such as arsenic and lead, as non-hazardous waste. The label means that states, and not the EPA, will be the primary enforcers of the new rules, which will require the closure of some coal ash holding ponds...

  • National Labor Relations Board on Friday filed complaints against McDonald's Corp and its franchises for alleged labor violations, including the illegal firing and intimidation of staff who protested working conditions. NLRB General Counsel Richard Griffin filed complaints in 78 cases against the company and its franchisees from New York to Los...

  • WASHINGTON— The National Labor Relations Board on Friday designated McDonald's Corp. as a "joint-employer" with franchisees at nearly 14,000 U.S. restaurants, delivering a big win to unions. The board's general counsel's office ruled that the company violated the rights of employees openly seeking better pay and working conditions. It disclosed in July it...

  • Dec 19- A lawyer from the U.S. National Labor Relations Board on Friday filed complaints against McDonald's Corp and its franchisees for alleged labor violations. NLRB General Counsel Richard Griffin filed 13 complaints against the company and its franchisees from New York to Los Angeles, the board said.

  • NATIONAL LABOR RELATIONS BOARD OFFICIAL ISSUES COMPLAINTS AGAINST MCDONALDS FOR ALLEGED LABOR VIOLATIONS BY FRANCHISEES- FILING.

  • Volcker critical of delays in namesake rule Friday, 19 Dec 2014 | 12:33 PM ET

    WASHINGTON— Former Federal Reserve Chairman Paul Volcker on Friday criticized a decision to delay full implementation of a rule that bears his name and aims to curb banks' risky investments. The Fed said Thursday that it would delay until July 2017 the deadline by which U.S. banks will have to sell off potentially volatile holdings in private equity, venture...

  • Dec 19- AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after it was approved by the European Commission. An advisory panel to the U.S. Food and Drug Administration had voted in June against granting an accelerated approval to the drug, Lynparza, citing inadequate data. Lynparza aims to treat...